Dhanuka Agritech (507717) M&A Announcement summary
Event summary combining transcript, slides, and related documents.
M&A Announcement summary
19 Jun, 2026Deal rationale and strategic fit
Acquisition of international rights for Iprovalicarb and Triadimenol aims to expand presence in over 20 countries, including key markets in Latin America, MENA, Europe, Asia, and India.
Expanding from a domestic to a global player aligns with the long-term vision to increase international presence and leverage existing customer bases for future product launches.
Acquisition of two Bayer fungicides with established registrations and customer base accelerates global market entry and strengthens product portfolio.
Access to established brands and markets, especially in Brazil and Asia, provides entry barriers for competitors.
Financial terms and conditions
Total purchase price for both products is approximately INR 167 crore.
Combined global revenue for these products was about INR 224 crore in 2023, with an estimated decline to INR 186 crore in 2024.
Peak revenue reached INR 245 crore in 2022.
Synergies and expected cost savings
Manufacturing of Iprovalicarb will be shifted to India, utilizing the Dahej facility, and plans include sourcing technical ingredients from generic suppliers to reduce costs.
Expected to maintain EBITDA margins at current levels despite slightly lower gross margins.
Latest events from Dhanuka Agritech
- Q2 profit rose despite monsoon disruption; FY27 guidance remains cautious and H1 included a ₹70 crore buyback.507717
Q2 26/27 - Profit rose despite liquidity strain; launches and monsoon hopes shaped the outlook.507717
Q4 98/99 - Sales rose 36% and net profit more than doubled despite pesticide-sector setbacks.507717
Q4 97/98 - Turnover declined and the year ended in a Rs 171.23 lakh loss amid industry headwinds.507717
Q4 00/01 - Higher finance costs cut profit despite turnover growth; new products and monsoon hopes underpin outlook.507717
Q4 99/00 - Lower costs narrowed losses, but monsoon disruption and Haryana tax clouded growth.507717
Q4 01/02 - Turnover rose and profitability returned despite a difficult monsoon year.507717
Q4 02/03 - Merged FY 2006-07 PAT rose ~28%, with monsoon and new capacity shaping the outlook.507717
Q4 06/07 - Turnover grew 9.23%, PBT surged, and monsoon risk shaped the outlook.507717
Q4 03/04 - DHAWA-led growth lifted FY05 turnover 86.57%, while weak operating cash flow highlighted working-capital pressure.507717
Q4 04/05